Tervisetehnoloogiate Arenduskeskus

What Tervisetehnoloogiate Arenduskeskus does

Celvia (legal entity Celvia CC AS, formerly Tervisetehnoloogiate Arenduskeskus) is an Estonian clinical genomics laboratory and research institution headquartered in Tartu. The company develops and delivers a portfolio of proprietary genetic and reproductive health tests under the brand names NIPTIFY (non-invasive prenatal screening for fetal chromosomal abnormalities from maternal blood), beREADY (personalized fertility treatment planning), PGT-A (preimplantation embryo selection), CLARITY (chromosomal cause-of-pregnancy-loss testing from week 6), InvisibleMi (reproductive tract microbiome analysis), and Mee DNA Analüüs/MDA (honey authenticity via DNA metagenomics). Underlying technology combines DNA sequencing, metagenomics, and bioinformatics pipelines, with delivery supported by ISO 15189:2022 and ISO 17025:2017 certifications and IVD marking on core tests. Celvia is co-owned by Tartu University and Tartu University Hospital and reports over 300 scientific publications, with a high share of PhD-level staff.

The business operates as a B2B2C/direct clinical lab, charging per-test fees (pricing not publicly disclosed) and distributing through Estonian regional hospitals, fertility clinics, and private healthcare providers, alongside consumer-direct ordering via dedicated product websites (niptify.ee, beready.ee, invisiblemi.eu, mda-test.com). Its three primary customer segments are pregnant women/expecting parents, fertility clinics and couples undergoing IVF, and (non-core) honey producers and food-safety bodies. Revenue model is one-time per-test payments. Commercial operations are Estonia-only per disclosed market data, though the company maintains research collaborations with European universities (Maastricht, KU Leuven, Oulu, Granada, Lithuanian University of Health Sciences, Riga Stradins) and partners with international labs (Eurofins Genoma, Igenomix).

The company is privately held with no external funding rounds disclosed and is operated as a for-profit clinical and research enterprise positioned between academic research and applied medicine. Marketing relies on Estonian TV/print/radio earned media and Facebook/Instagram organic presence, with a sales-led go-to-market into hospital and clinic channels.

Name

Tervisetehnoloogiate Arenduskeskus

Legal name

Celvia CC AS

Website

https://ccht.ee

Company type

Private

Founded year

2009

Operating status

Operating

Headcount range

11–50 employees

Short description

Celvia (formerly Tervisetehnoloogiate Arenduskeskus) is an Estonian clinical genomics laboratory in Tartu that develops and delivers proprietary non-invasive prenatal, fertility, and microbiome genetic tests, plus honey DNA authentication, to Estonian hospitals, fertility clinics, and consumers.

Ownership category

akta.pro rank

Product category

Genetic Testing Services

NAICS

Medical Laboratories (621511), Medical and Diagnostic Laboratories (6215), Research and Development in Biotechnology (except Nanobiotechnology) (541714)

SIC

Services-Medical Laboratories (8071), Services-Testing Laboratories (8734), In Vitro & In Vivo Diagnostic Substances (2835)

akta.pro primary industry

Genetic & Prenatal Testing Laboratories (HLAFAMAH)

akta.pro secondary industries

Prenatal, Newborn & Reproductive Diagnostics (NIPT, IVF/PGT, newborn screening) (HLAAALAJ), Genetic & Genomic Testing (germline, somatic, carrier, pharmacogenomics) (HLAAALAD), Genetic, Cytogenetic & Prenatal Screening IVD (HLAHAAAI), Supplier Approval, Verification & Food Safety Risk Management (GFSI-aligned) (AFALADAH)

Keywords

• Genetic testing services
• Prenatal screening tests
• Fertility genetic testing
• DNA metagenomic analysis
• Precision medicine diagnostics

Headquarters

HQ city

Tartu

HQ country

Estonia

HQ region

Europe

Offices1 record

Markets served

GTM type

B2B

Offering type

Services

Cost components

Personnel, Technology or R&D, Operations, Infrastructure, Others

Revenue model

1. Genetic Testing Services: Revenue generated from selling genetic testing products and services including NIPTIFY (prenatal screening), beREADY (fertility testing), InvisibleMi (microbiome testing), PGT-A (preimplantation testing), and honey DNA analysis (MDA). Tests are offered to patients, clinics, and healthcare providers.

Go-to-market motion1 record

Distribution channels2 records

Marketing channels4 records

Core offering

Celvia (formerly Tervisetehnoloogiate Arenduskeskus) develops and delivers a portfolio of proprietary genetic and precision medicine diagnostic tests, including non-invasive prenatal screening (NIPTIFY), fertility treatment planning (beREADY, PGT-A), reproductive microbiome analysis (InvisibleMi), chromosomal analysis of pregnancy loss (CLARITY), and honey authenticity verification through DNA metagenomics (MDA). The company operates as both a medical and testing laboratory, offering these services to patients, fertility clinics, hospitals, and food-safety bodies across Estonia and partner networks internationally.

Product overview

Celvia (formerly Tervisetehnoloogiate Arenduskeskus) offers a portfolio of genetic and precision medicine tests. The product suite includes: NIPTIFY (non-invasive prenatal testing for fetal chromosomal diseases), BeReady and PGT-A Test (fertility treatment solutions for embryo selection and transfer planning), CLARITY (pregnancy loss chromosomal analysis), InvisibleMi (reproductive tract microbiome testing), and Mee DNA Analüüs/MDA (honey composition and authenticity testing). These products are developed combining scientific research with modern technology for healthcare and food safety applications.

Differentiator

Problem solved

Functional benefit

Brands

• NIPTIFY: A precise and safe genetic test that analyzes the most significant fetal chromosomal diseases from a single maternal blood sample.
• beREADY
• InvisibleMi
• PGT-A Test
• Mee DNA Analüüs (MDA)
• CLARITY

Products and services

• NIPTIFY A precise and safe non-invasive prenatal screening test that analyses the most significant fetal chromosomal diseases using a single maternal blood sample; intended for pregnant women and their clinicians.
• beREADY Personalised medicine test used in fertility treatment to plan embryo transfers and create treatment plans; intended for fertility clinics and couples undergoing IVF.
• InvisibleMi A private diagnostic test that detects and monitors the microbial community of female and male reproductive tracts; intended for fertility clinics and patients undergoing reproductive health evaluation.
• PGT-A Test A precision medicine preimplantation genetic test for aneuploidy used in fertility treatment to select embryos with healthy chromosomal makeup for transfer; intended for IVF clinics and patients.
• Mee DNA Analüüs (MDA) A DNA metagenomic analysis test providing a comprehensive picture of honey composition and origin and helping to identify honey counterfeits; intended for honey producers, distributors, and food-safety regulatory bodies.
• CLARITY An innovative non-invasive test for identifying chromosomal causes of pregnancy loss from week 6 of pregnancy, requiring only one blood sample; intended for clinicians and patients investigating miscarriage causes.

Quantifiable outcome

• Detection of major fetal chromosomal diseases through single maternal blood sample
• +2 more outcomes

Named customers9 records

Segments3 records

Ideal customer profiles3 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature6 records

Partnerships

19 partnerships are on record, tiered core and supporting.

• Tartu Ülikool (Tartu University)coreStrategic or Co-development PartnerCo-owner of Celvia; primary research partner providing scientific expertise and academic foundation for genetic testing development; collaboration on basic and applied research in biomedicine and molecular biology
• Tartu Ülikooli Kliinikum (Tartu University Hospital)coreStrategic or Co-development PartnerCo-owner of Celvia; key clinical partner providing medical expertise and facilitating translation of research into clinical applications; essential for product validation and clinical testing
• Taltech (Tallinn University of Technology)supportingTechnology or IntegrationAcademic partner for research collaboration in technology and engineering domains related to genetic testing and bioinformatics
• Maastricht UniversitysupportingStrategic or Co-development PartnerInternational academic research partner contributing to scientific studies and research publications in reproductive genetics and developmental biology
• Oulu UniversitysupportingStrategic or Co-development PartnerInternational academic research partner for studies in biomedicine and genetics research collaboration
• KU LeuvensupportingStrategic or Co-development PartnerInternational academic partner contributing to research excellence in life sciences and genetic research
• Granada UniversitysupportingStrategic or Co-development PartnerInternational academic research partner for scientific collaboration in genetics and reproductive health
• Lithuanian University of Health SciencessupportingStrategic or Co-development PartnerInternational academic partner in Baltic region for research collaboration in health sciences and genetics
• Riga Stradins UniversitysupportingStrategic or Co-development PartnerInternational academic partner for research collaboration in biomedical sciences and genetics
• Eurofins GenomasupportingTechnology or IntegrationInternational laboratory partner for genetic testing services and laboratory analysis collaboration
• IgenomixsupportingTechnology or IntegrationInternational partner specialized in reproductive genetics and preimplantation genetic testing technology
• GenerasupportingTechnology or IntegrationPartner in fertility testing and reproductive health technology solutions
• MelivasupportingTechnology or IntegrationHealthcare laboratory services partner for diagnostic and testing services collaboration
• Pärnu HaiglasupportingChannel Partner/ Reseller/ DistributorRegional hospital partner providing access to genetic testing services for patients in Pärnu region
• Ida-Viru KeskhaiglasupportingChannel Partner/ Reseller/ DistributorRegional hospital partner providing access to genetic testing services for patients in Ida-Viru region
• ITK (Ida-Tallinna Keskhaigla)supportingChannel Partner/ Reseller/ DistributorRegional hospital partner providing access to genetic testing services for patients in Tallinn region
• ConfidosupportingChannel Partner/ Reseller/ DistributorPrivate healthcare provider partner offering genetic testing services to patients
• FertilitassupportingChannel Partner/ Reseller/ DistributorFertility clinic partner for reproductive genetics and fertility treatment testing services
• EMU (Estonian University of Life Sciences)supportingStrategic or Co-development PartnerAcademic partner for research collaboration including honey DNA analysis and agricultural genomics applications

Scale indicators4 records

Recent moves7 records

Expansion highlights5 records

Direct peers

• Igenomix: Global reproductive genetics specialist offering PGT-A, NIPT, and carrier screening. Direct competitor and current technology partner to Celvia in preimplantation and prenatal testing.
• Natera: Commercial leader in NIPT (Panorama) and reproductive genetics with global clinical reach. Most direct scaled rival to NIPTIFY and beREADY in the prenatal and IVF testing market.
• Eurofins Genoma: European laboratory genetics provider offering NIPT, PGT, and carrier screening. Directly overlaps with Celvia's core reproductive genetics menu and is also a listed partner.
• Premaitha Health (Yourgene Health): UK-based NIPT provider (formerly Premaitha) offering the Iona test, focused on European clinical laboratories. Closely comparable niche player to NIPTIFY in regional NIPT markets.

Emerging players

• Genera: Brazil-based reproductive genetics and fertility testing company. Listed as a Celvia partner in fertility testing; serves a similar niche with comparable PGT and reproductive health offerings.

Broad incumbents

• Myriad Genetics: Established clinical genetic testing company with hereditary cancer, reproductive, and pharmacogenomic tests. Broad incumbent in the molecular diagnostics category Celvia operates in.
• BGI Genomics: Global genomics powerhouse with NIFTY (NIPT) and high-volume genetic testing. Comparable on test menu (NIPT, PGT, carrier) and operates at vastly larger scale.
• Invitae: Large clinical genetics laboratory offering a broad menu including reproductive and carrier screening. Competes with Celvia for hospital and clinic accounts across reproductive indications.
• Vitrolife: Global IVF and reproductive medicine supplier with PGT-related products and services. Overlaps with Celvia's PGT-A and beREADY offerings in the IVF clinic channel.
• CooperSurgical (PGT division): Fertility and genomics provider offering PGT-A services through its genetics platform. Direct overlap with Celvia's PGT-A Test and fertility-focused beREADY.

Market position

Strengths4 records

Weaknesses4 records

Competitive moat5 records

Key risks5 records

Key highlights6 records

Customer concentration

• Facebookfacebook.com/meditsiinilabor
• Instagraminstagram.com/celvialaboratory

Compliance3 records

Revenue estimate

Valuation estimate

Number of profiles

Profiles5 records

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Tervisetehnoloogiate Arenduskeskus